<p>Senior Research Associate, Analytical Chemistry</p> <p>Position Description: We are seeking an Analytical Chemist to provide laboratory support for non-GMP formulation development activities, routine discovery needs as well as development of new test procedures. Most testing will be conducted using RP-HPLC and dissolution equipment.</p> <p>Primary Responsibilities:</p> <ul> <li>Support routine analysis for discovery (e.g., dose solution analysis, stability, and solubility samples) by HPLC. </li><li>Develop and implement analytical methodologies supporting internal process chemistry and formulation development activities, with a focus on HPLC and dissolution testing. </li><li>Develop key, early clinical stage analytical methods that can be transferred and validated at Contract Manufacturing Organizations. </li><li>Provide guidance and methodologies to non-analytical colleagues and communicate results in a manner that provides context and guides the next experimental steps. </li><li>Maintain organized records to track cross-functional research analytical data. </li></ul> <p>Experience in these areas is a plus:</p> <ul> <li>Knowledge of QC functions. </li><li>Knowledge of peptide analytical chemistry. </li><li>Expertise in dissolution testing and other solid oral dose form analytical tools. </li><li>Experience with Agilent LC equipment and OpenLab CDS software. </li></ul> <p>Job Requirements:</p> <ul> <li>BS or with at least 5 - 7 years in Analytical Chemistry. </li><li>Must be able to communicate scientific data and ideas as well as maintain a competent laboratory notebook. </li><li>HPLC experience. </li><li>Proficient computer skills. </li><li>Strong focus on quality and attention to detail. </li></ul> <p>The base pay range for this position at commencement of employment is expected to be between $110,000 and $120,000 / year; however, base pay offered may vary depending on multiple individualized factors, including market location, job-related knowledge, skills, and experience.</p> <p>Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides, icotrokinra and rusfertide, derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA expected in 2025. Icotrokinra (JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ("IL-23R") which is licensed to Janssen Biotech, Inc., a Johnson & Johnson company. Following icotrokinra's joint discovery by Protagonist and Johnson & Johnson scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with Johnson & Johnson assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered into in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage oral drug discovery programs addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.</p>